Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus

Blood

Volumn 106, Issue 13, 2005, Pages 4339-4344

  Mancao, Christoph ^b   Altmann, Markus ^b   Jungnickel, Berit ^b   Hammerschmidt, Wolfgang ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN;

ALLELE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL CYCLE; CONTROLLED STUDY; DELETION MUTANT; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GERMINAL CENTER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOBLASTOID CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS INFECTION;

EID: 28844502383     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2341     Document Type: Article

References (46)

1. Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan IC. Mechanism of antigendriven selection in germinal centres. Nature. 1989;342:929-931.
2. Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell. 2004;117:787-800.
3. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000;95:1443-1450.
4. Bräuninger A, Küppers R, Strickler JG, Wacker HH, Rajewsky K, Hansmann ML. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci U S A. 1997;94:9337-9342.
5. Kanzler H, Küppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184:1495-1505.
6. Kieff E, Rickinson AB. Epstein-Barr virus and its replication. In: Knipe DM, Howley PM, Griffin DE, Straus SE, eds. Fields' Virology. Vol 2. 4th ed. Philadelphia, PA: Lippincott-Williams & Wilkins; 2001:2511-2573.
7. Herbst H, Dallenbach F, Hummel M, et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci U S A. 1991;88:4766-4770.
8. Niedobitek G, Kremmer E, Herbst H, et al. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood. 1997;90:1664-1672.
9. Brink AA, Dukers DF, van den Brule AJ, et al. Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas. J Clin Pathol. 1997;50:911-918.
10. Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 1998;17:1700-1709.
11. Hammerschmidt W, Sugden B. Epstein-Barr virus sustains Burkitt's lymphomas and Hodgkin's disease. Trends Mol Med. 2004;10:331-336.
12. Gires O, Zimber-Strobl U, Gonnella R, et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 1997;16:6131-6140.
13. Fruehling S, Longnecker R. The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology. 1997;235:241-251.
14. Reth M. Antigen receptor tail clue. Nature. 1989;338:383-384.
15. Cambier JC. Antigen and Fc receptor signaling: the awesome power of the immunoreceptor tyrosine-based activation motif (ITAM). J Immunol. 1995;155:3281-3285.
16. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity. 1998;9:405-411.
17. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci U S A. 1998;95:8245-8250.
18. Dirmeier U, Hoffmann R, Kilger E, et al. Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis. Oncogene. 2005;24:1711-1717.
19. Banchereau J, de Paoli P, Valle A, Garcia E, Rousset F. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science. 1991;251:70-72.
20. Küppers R. Molecular single-cell PCR analysis of rearranged immunoglobulin genes as a tool to determine the clonal composition of normal and malignant human B cells. In: Gu H, Rajewsky K, eds. Methods Molecular Biology. Vol 271. Totowa, NJ: Humana Press; 2004:225-238.
21. Müschen M, Rajewsky K, Bräuninger A, et al. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med. 2000;191:387-394.
22. Zimber-Strobl U, Kempkes B, Marschall G, et al. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J. 1996;15:7070-7078.
23. Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin's lymphoma-molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol. 2004;5:11-18.
24. Küppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol. 2003;3:801-812.
25. Katamine S, Otsu M, Tada K, et al. Epstein-Barr virus transforms precursor B cells even before immunoglobulin gene rearrangements. Nature. 1984;309:369-372.
26. Hansson M, Falk K, Ernberg I. Epstein-Barr virus transformation of human pre-B cells. J Exp Med. 1983;158:616-622.
27. Gregory CD, Kirchgens C, Edwards CF, et al. Epstein-Barr virus-transformed human precursor B cell lines: altered growth phenotype of lines with germ-line or rearranged but nonexpressed heavy chain genes. Eur J Immunol. 1987;17:1199-1207.
28. Ehlin-Henriksson B, Gordon J, Klein G. B-lymphocyte subpopulations are equally susceptible to Epstein-Barr virus infection, irrespective of immunoglobulin isotype expression. Immunology. 2003;108:427-430.
29. Mangeney M, Richard Y, Coulaud D, Tursz T, Wiels J. CD77: an antigen of germinal center B cells entering apoptosis. Eur J Immunol. 1991;21:1131-1140.
30. Lebecque S, de Bouteiller O, Arpin C, Banchereau J, Liu YJ. Germinal center founder cells display propensity for apoptosis before onset of somatic mutation. J Exp Med. 1997;185:563-571.
31. Zarnegar B, He JQ, Oganesyan G, Hoffmann A, Baltimore D, Cheng G. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc Natl Acad Sci U S A. 2004;101:8108-8113.
32. Rajewsky K. Clonal selection and learning in the antibody system. Nature. 1996;381:751-758.
33. Merchant M, Swart R, Katzman RB, et al. The effects of the Epstein-Barr virus latent membrane protein 2A on B cell function. Int Rev Immunol. 2001;20:805-835.
34. Casola S, Otipoby KL, Alimzhanov M, et al. B cell receptor signal strength determines B cell fate. Nat Immunol. 2004;5:317-327.
35. Muschen M, Rajewsky K, Brauninger A, et al. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med. 2000;191:387-394.
36. Kuppers R. Molecular biology of Hodgkin's lymphoma. Adv Cancer Res. 2002;84:277-312.
37. Martin JM, Veis D, Korsmeyer SJ, Sugden B. Latent membrane protein of Epstein-Barr virus induces cellular phenotypes independently of expression of Bcl-2. J Virol. 1993;67:5269-5278.
38. Allday MJ, Crawford DH, Griffin BE. Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. J Gen Virol. 1989;70:1755-1764.
39. Alfieri C, Birkenbach M, Kieff E. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology. 1991;181:595-608.
40. Altmann M, Hammerschmidt W. Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol. In press.
41. Bechtel D, Kurth J, Unkel C, Kuppers R. Transformation of BCR-deficient germinal center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and post transplant lymphoma. Blood. Prepublished on August 30, 2005, as DOI 10.1182/blood-2005-06-2342.
42. Chaganti S, Bell AI, Begue-Pastor N, et al. Epstein-Barr virus infection in vitro can rescue germinal centre B cells with inactivated immunoglobulin genes. Blood. Prepublished on August 25, 2005, as DOI 10.1182/blood-2005-06- 2327.
43. Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med. 1993;177:339-349.
44. Grasser FA, Murray PG, Kremmer E, et al. Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood. 1994;84:3792-3798.
45. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet. 1991;337:320-322.
46. Babcock GJ, Hochberg D, Thorley-Lawson AD. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity. 2000;13:497-506.